Vitrolife AB (SE:VITR)
:VITR
Want to see SE:VITR full AI Analyst Report?
VITR Stock Chart & Stats
kr133.00
-kr3.40(-1.91%)
At close: 4:00 PM EST
kr133.00
-kr3.40(-1.91%)
Day’s Range― - ―
52-Week Rangekr84.60 - kr153.50
Previous CloseN/A
Volume81.91K
Average Volume (3M)92.36K
Market Cap
kr13.03B
Enterprise Valuekr14.09B
Total Cash (Recent Filing)kr886.00M
Total Debt (Recent Filing)kr1.58B
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Jul 16, 2026EPS Estimate
0.95Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)-37.01
Shares Outstanding135,447,190
10 Day Avg. Volume105,869
30 Day Avg. Volume92,365
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.35
Price to Sales (P/S)5.39
P/FCF Ratio50.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.08
Revenue Forecast (FY)kr3.48B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation (TTM)Consistent positive operating and free cash flow in the TTM provides durable financial flexibility. It supports organic investment, service and R&D spending, and buffers the business through cyclical revenue/earnings volatility without immediate reliance on external financing.
Low Leverage / Manageable DebtLow debt relative to equity reduces refinancing and interest-rate risk, preserving capacity for targeted capital expenditures or strategic M&A. Manageable leverage strengthens financial resilience and supports long-term operational continuity amid earnings pressure.
Recurring Consumables Business ModelA high-repeat consumables and media franchise creates stable, procedure-linked revenue streams and recurring demand. This structural stickiness supports long-term revenue visibility and margin sustainability versus one-off capital equipment sales.
Bears Say
Revenue Decline TrendSustained revenue weakness reduces scale economies and undermines long-term growth optionality. Declining top-line pressures capacity to cover fixed costs, slows investment in product development and geographic expansion, and can exacerbate margin and earnings volatility.
Weak And Volatile ProfitabilityPersistent large net losses despite healthy gross margins indicate issues converting product economics into operating profit. This undermines retained earnings, constrains shareholder returns, and may require ongoing cost cuts or structural fixes to restore sustainable profitability.
Erosion Of Equity / ReturnsMaterial decline in equity and negative shareholder returns signal balance-sheet stress from repeated losses. Equity erosion reduces financial cushions, limits strategic flexibility, and could increase the likelihood of dilutive capital raises if profitability and cash conversion don't sustainably recover.
Vitrolife AB News
VITR FAQ
What was Vitrolife AB’s price range in the past 12 months?
Vitrolife AB lowest stock price was kr84.60 and its highest was kr153.50 in the past 12 months.
What is Vitrolife AB’s market cap?
Vitrolife AB’s market cap is kr13.03B.
When is Vitrolife AB’s upcoming earnings report date?
Vitrolife AB’s upcoming earnings report date is Jul 16, 2026 which is in 33 days.
How were Vitrolife AB’s earnings last quarter?
Vitrolife AB released its earnings results on Apr 23, 2026. The company reported kr0.74 earnings per share for the quarter, missing the consensus estimate of kr0.773 by -kr0.033.
Is Vitrolife AB overvalued?
According to Wall Street analysts Vitrolife AB’s price is currently Overvalued.
Does Vitrolife AB pay dividends?
Vitrolife AB pays a Annually dividend of kr1.1 which represents an annual dividend yield of 0.8%. See more information on Vitrolife AB dividends here
What is Vitrolife AB’s EPS estimate?
Vitrolife AB’s EPS estimate is 0.95.
How many shares outstanding does Vitrolife AB have?
Vitrolife AB has 135,447,190 shares outstanding.
What happened to Vitrolife AB’s price movement after its last earnings report?
Vitrolife AB reported an EPS of kr0.74 in its last earnings report, missing expectations of kr0.773. Following the earnings report the stock price went up 12.265%.
Which hedge fund is a major shareholder of Vitrolife AB?
Currently, no hedge funds are holding shares in SE:VITR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vitrolife AB
Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such as oocyte retrieval needles, sperm processing solutions, specialized in vitro fertilization media and oils, and micromanipulation pipettes. The company also provides general labware, incubators, cryopreservation products, and systems for preimplantation genetic testing. Furthermore, Vitrolife delivers advanced equipment, including the EmbryoScope and Primo Vision time-lapse systems, along with dedicated dishes and evaluation software for these platforms. Their technology portfolio extends to Octax laser and imaging systems, as well as environmental monitoring solutions like log and guard systems and wireless sensors. With its headquarters located in Gothenburg, Sweden, Vitrolife maintains a significant international presence, operating across Europe, the Middle East, and Africa; Asia; Japan and the Pacific; and both North and South America. Founded in 1994, the company was initially known as Scandinavian IVF Science before officially changing its name to Vitrolife AB (publ) in 1998.
Technical Analysis
Getinge
―
BICO Group AB Class B
―
CellaVision AB
―
Xvivo Perfusion AB
―
Sectra AB Class B
―
Options Prices
Currently, No data available
---